20 June 2013Patents

European Commission targets alleged ‘pay-for-delay’ with pharma fines

The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

US Supreme Court backs ‘rule-of-reason’ for pay-for-delay

17 June 2013 A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.

Patents

OFT accuses GSK of market abuse over pay-for-delay deals

19 April 2013 The UK Office of Fair Trading has accused GlaxoSmithKline of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat.

UK-India trade deal is ‘missed opportunity’, say industry bodies

SEPs now searchable on WIPO’s global patent database

'Nothing can stand in the way of our work': Ukraine resumes IP system

WATCH: Finding a new balance in IP protection with trade secret protection

Optis v Apple: How the court calculated the royalty rate

Apple must pay Optis $700m-the biggest patent award in UK history

Wouter Pors leaves Bird & Bird for boutique Dutch firm

US-China tariffs: What hope is there for IP rightsholders?

European Commission targets alleged ‘pay-for-delay’ with pharma fines

More on this story

Editor's picks

Editor's picks

More articles